Pain News and Research

Latest Pain News and Research

More opioids being prescribed for pain relief in Germany

More and more opioids are being prescribed for pain relief in Germany. This is the conclusion arrived at by Ingrid Schubert, Peter Ihle, and Rainer Sabatowski, whose study of a sample of inhabitants of the state of Hesse with health insurance from a large statutory provider is published in the latest issue of Deutsches Ärzteblatt International.

13 Feb 2013

Exposure to harmful quantities of lead may lead to juvenile delinquency

Lead is a common element but is found in old paints (including those once used on children's toys), soil, old piping, water, and the atmosphere from lead-containing vehicular fuels, even drinking vessels. At high dose it is lethal but also causes seemingly trivial symptoms such as headaches. However, in children lead can also lead to irreversible damage to the organs, the kidneys in particular, and the nervous system including the brain.

13 Feb 2013

Tips for menopausal women to better enjoy their sex lives

Menopause can be a real rollercoaster—and that can impact women's sex lives. It can cause women's libidos to climb, suddenly drop, and then climb again due to the combination of estrogen and women's own levels of testosterone powering this wild cycle.

13 Feb 2013

LASAG trial for severe influenza initiated

...

12 Feb 2013

Piroxicam ultrasound combination optimal for knee osteoarthritis

Phonophoresis of the non steroidal anti-inflammatory drug piroxicam with ultrasound is more effective than ultrasound alone for improving pain and other symptoms of mild-to-moderate knee osteoarthritis, show study findings.

12 Feb 2013

New video features 5 chemistry facts that highlight chocolate’s beneficial properties

Just in time for Valentine's Day, the American Chemical Society (ACS), the world's largest scientific society, released a new Bytesize Science video today featuring five chemistry facts that highlight why chocolate, in moderation, may be good for you.

12 Feb 2013

Selumetinib shows high response rate for patients with low-grade serous ovarian cancer

Low-grade serous ovarian cancer is less common and aggressive than the high-grade variety, yet exceptionally difficult to treat when frontline therapy fails.

11 Feb 2013

Symposium to discuss new techniques for assessing risk of acute kidney injury

Leading critical care experts will discuss new techniques for assessing risk of acute kidney injury (AKI) at an educational symposium to be held at the Eighteenth International Conference on Continuous Renal Replacement Therapies (CRRT) in San Diego.

11 Feb 2013

FDA hears concerns on new narcotic pain pill rules

Survivors of those who died from opioid overdoses urge changes in the drugs' labels, but some patients express concerns that they might have trouble getting the drugs.

11 Feb 2013

Epithelium able to sense bladder fullness through activity of integrins

If you have an overactive bladder or incontinence, help could be on the way. A new research report published online in the FASEB Journal, shows that the epithelium, a thin layer of cells which line the surface of the bladder, is able to sense how full the bladder is through the action of a family of proteins called integrins.

11 Feb 2013

Study identifies 12 important postoperative complication signs in colorectal surgical patients

Colorectal surgical patients are often discharged from the hospital with vague guidance on how to recognize complications, but researchers at the Michael DeBakey Veterans Administration (VA) Medical Center and Baylor College of Medicine, Houston, aim to change that scenario.

11 Feb 2013

Biogen Idec, Sobi release data from rFVIIIFc and rFIXFc phase 3 trials on hemophilia

Biogen Idec and Swedish Orphan Biovitrum (Sobi) released data that confirmed the ability of investigational recombinant factors VIII Fc fusion protein (rFVIIIFc) and IX Fc fusion protein (rFIXFc) to provide long-lasting protection from bleeding with fewer injections than are required with the current standard of care for people with hemophilia.

10 Feb 2013

Research sheds light on how E. coli thrive in the intestine of people with IBD

Scientists have long puzzled over why "bad" bacteria such as E. coli can thrive in the guts of those with inflammatory bowel disease (IBD), causing serious diarrhea. Now UC Davis researchers have discovered the answer-one that may be the first step toward finding new and better treatments for IBD.

10 Feb 2013

Many pregnant women with sexually transmitted infections do not get needed treatment

Many pregnant women with sexually transmitted infections aren't getting the treatment they need when they visit emergency rooms, according to a new Michigan State University study that highlights a wholly preventable risk to unborn children and raises questions about current medical guidelines.

10 Feb 2013

NGOs document thousands of cases of Indian women undergoing unnecessary hysterectomies, C-sections

"Thousands of women in India are being given hysterectomies and caesareans that they do not need by doctors and hospitals that can make substantial sums of money out of the operations," Guardian health editor Sarah Boseley reports in her "Global Health Blog."

10 Feb 2013

Research roundup: 'Shared decision making' can reduce costs, improve care; Effects of mental health parity

With shared decision making, patients and their clinicians collaboratively review the risks and benefits of available treatments options while also considering the patients' preferences and values.

10 Feb 2013

Celgene's Pomalyst receives FDA approval for treatment of multiple myeloma

The U.S. Food and Drug Administration today approved Pomalyst (pomalidomide) to treat patients with multiple myeloma whose disease progressed after being treated with other cancer drugs.

10 Feb 2013

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Celgene Corporation today announced the U.S. Food and Drug Administration (FDA) has approved POMALYST brand therapy (pomalidomide) for patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of the last therapy.

10 Feb 2013

Shire commences ABH001 Phase 3 study in Epidermolysis Bullosa

Shire plc, today announced the initiation of a Phase 3 study designed to evaluate the efficacy and safety of ABH001, its dermal substitute therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), a group of rare genetic skin disorders that begin to manifest at birth or early childhood and occur in approximately 19 per 1 million live births in the US.

10 Feb 2013

Neurocrine Biosciences fourth quarter net income increases to $9.5 million

Neurocrine Biosciences, Inc. today announced its financial results for the quarter and year ended December 31, 2012.

9 Feb 2013

Pain News and Research

Latest Pain News and Research

More opioids being prescribed for pain relief in Germany

Exposure to harmful quantities of lead may lead to juvenile delinquency

Tips for menopausal women to better enjoy their sex lives

LASAG trial for severe influenza initiated

Piroxicam ultrasound combination optimal for knee osteoarthritis

New video features 5 chemistry facts that highlight chocolate’s beneficial properties

Selumetinib shows high response rate for patients with low-grade serous ovarian cancer

Symposium to discuss new techniques for assessing risk of acute kidney injury

FDA hears concerns on new narcotic pain pill rules

Epithelium able to sense bladder fullness through activity of integrins

Study identifies 12 important postoperative complication signs in colorectal surgical patients

Biogen Idec, Sobi release data from rFVIIIFc and rFIXFc phase 3 trials on hemophilia

Research sheds light on how E. coli thrive in the intestine of people with IBD

Many pregnant women with sexually transmitted infections do not get needed treatment

NGOs document thousands of cases of Indian women undergoing unnecessary hysterectomies, C-sections

Research roundup: 'Shared decision making' can reduce costs, improve care; Effects of mental health parity

Celgene's Pomalyst receives FDA approval for treatment of multiple myeloma

Celgene receives FDA approval for POMALYST to treat multiple myeloma

Shire commences ABH001 Phase 3 study in Epidermolysis Bullosa

Neurocrine Biosciences fourth quarter net income increases to $9.5 million

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Pain News and Research

Latest Pain News and Research

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Newsletters you may be interested in